Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.

about

Lenalidomide and Temozolomide Combination in a Very Elderly Patient with CNS Relapse of Diffuse Large B-Cell Lymphoma.

P2860

Q38658898-FC44A3D4-CA9F-4712-B7D1-F5C6949698A8

P2860

Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.

Item

http://www.wikidata.org/entity/Q40332965

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Upfront lower dose lenalidomid ...... of the phase II RevLite study.

@en

type

Item

label

Upfront lower dose lenalidomid ...... of the phase II RevLite study.

@en

prefLabel

Upfront lower dose lenalidomid ...... of the phase II RevLite study.

@en

P1476

Upfront lower dose lenalidomid ...... of the phase II RevLite study.

@en

P2093

Annette Neylon

http://www.w3.org/2001/XMLSchema#string

Arlene Swern

http://www.w3.org/2001/XMLSchema#string

Bart Baker

http://www.w3.org/2001/XMLSchema#string

Cecily Forsyth

http://www.w3.org/2001/XMLSchema#string

Craig Underhill

http://www.w3.org/2001/XMLSchema#string

Emma Link

http://www.w3.org/2001/XMLSchema#string

Gillian Corbett

http://www.w3.org/2001/XMLSchema#string

H Miles Prince

http://www.w3.org/2001/XMLSchema#string

Hang Quach

http://www.w3.org/2001/XMLSchema#string

Hilary Blacklock

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma.

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.

P304

441-448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14562

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Simon Harrison

J Trotman

P577

2017-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28197996

http://www.w3.org/2001/XMLSchema#string

Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.

about

P2860

P2860

Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698